Innate Pharma Marseille Stock Price, News & Analysis

Innate Pharma S.A. (IPHYF) is identified in regulatory filings as Innate Pharma S.A., a foreign private issuer that reports to the U.S. Securities and Exchange Commission on Form 20-F. The company appears in SEC filings under the name Innate Pharma S.A. and files current reports on Form 6-K as a foreign issuer.

According to its SEC disclosures, Innate Pharma S.A. is based in Marseille, France. Its principal executive office is located in Marseille, and the company provides English and French versions of its name in filings, indicating that it is a French company that also communicates with international investors.

Innate Pharma S.A. files Form 6-K current reports that reference press releases as exhibits. These filings show that the company uses SEC submissions to provide updates to investors and the market, with exhibits labeled as press releases attached to the 6-K reports.

The company’s filings include detailed financial and structural information prepared under IFRS, with references to ordinary shares, preference shares, issued capital, share premium, retained earnings, and accumulated other comprehensive income. The filings also reference various members or counterparties, such as Sanofi Aventis, Novo Nordisk A/S, MedImmune Limited, Bpifrance Participations, SICAV and mutual funds, and different categories of shareholders and financing arrangements. These references indicate that Innate Pharma S.A. discloses information about its capital structure, financing agreements, lease obligations, and relationships with institutional and other shareholders in its regulatory reports.

Innate Pharma S.A. also reports on intangible assets in its filings, including licences and intangible assets under development, as well as tangible assets such as land and buildings, laboratory equipment and other equipment, construction in progress, and right-of-use assets. The filings further mention loan agreements and lease financing obligations with various financial institutions and for different types of assets.

Innate Pharma S.A. is associated with the over-the-counter symbol IPHYF for investors who track the company’s stock. While industry and sector classifications are not specified in the provided data, the company’s detailed IFRS-based financial reporting and references to licensing agreements and intangible assets suggest a focus on activities that involve significant intellectual property and long-term development projects, as reflected in its SEC filings.